Research
Engaging in multidisciplinary research to advance amyloidosis knowledge.
Innovative Clinical Research
Our program conducts innovative clinical and basic science research within a multi-disciplinary framework to advance knowledge of amyloidosis. We foster an environment to enhance participation in local and multi-center clinical research trials and registries, with the goal of improving patient outcomes and access to evidence-based care practices. We support networking activities for researchers to connect, collaborate, and share ideas, while providing opportunities for patients to become involved in research.
Learn more about our publications and the grants we’ve received here
Research Areas of Focus
Our primary area of focus is clinical research, including clinical trials and registries.
Our researchers collaborate across disciplines and with other institutions to conduct local and multi-center clinical research projects with the goal of improving patient outcomes.
Our imaging and diagnostic research efforts focus on developing new diagnostic techniques and enhancing utilization of existing ones. We use advanced imaging technology to investigate the pathology of amyloidosis and develop more accurate diagnostic tools and surveillance approaches.
Our geriatric research activities aim to improve the care and treatment of older patients with amyloidosis. Our researchers work to identify the unique challenges faced by this patient population and develop interventions to improve their outcomes.
We conduct outcomes research to understand the effectiveness of various treatments and interventions for amyloidosis patients. Our researchers collect and analyze data on patient outcomes, including patient reported outcomes, to improve evidence-based care practices.
This category encompasses basic science research activities related to amyloidosis, including studies on the pathology and mechanisms of the disease. Our researchers work to deepen our understanding of the disease and identify new targets for therapy development.
This category encompasses basic science research activities related to amyloidosis, including studies on the pathology and mechanisms of the disease. Our researchers work to deepen our understanding of the disease and identify new targets for therapy development.
Current projects
Last updated 08/07/2024
| Project | Description | Type | Status |
|---|---|---|---|
| DepleTTR-CM | A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Amyloid Depleter ALXN2220 in Adult Participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | Clinical Trial | Active |
| MAGNITUDE | A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM | Clinical Trial | Active |
| Cardiac Amyloidosis Registry Study (CARS) | CARS is a is an observational, multi-center study designed to collect data and analyze it retrospectively on patients with AL or TTR cardiac amyloidosis. The study aims to Increase understanding of disease presentation, progression, and various treatment plans for AL and TTR cardiac amyloid through study of a large cohort of patients with AL and TTR amyloidosis, Identify demographic, hemodynamic, and organ-involvement data that are predictors of long-term survival, Compare the disease presentation, treatment strategies, and relative survival of AL and TTR amyloidosis patients. | Registry | Recruiting |
| The Canadian Registry for Amyloidosis Research (CRAR) | CRAR is a Canadian Investigator-initiated research study (registry) co-led by Dr. Nowell Fine (University of Calgary) and Dr. Margot Davis (University of British Columbia). This Canada-wide multidisciplinary research project aims to collect medical information on patients diagnosed with amyloidosis for the purpose of improving the quality-of-care patients receive, enhancing available resources and providing opportunities for future research. Data is collected from medical records and through self-reported patient outcomes, including quality of life indicators. This study is currently recruiting, and participation is open to all Canadian patients living with amyloidosis. | Registry | Recruiting |
| Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy (ATTR-ACT Trial) | A phase 3 multicenter, open label study to evaluate the safety of daily oral dosing of tafamidis meglumine 20 or 80 mg [or Tafamidis 61 mg] in subjects diagnosed with Transthyretin Cardiomyopathy (ATTR-ACT Extension Study). | Clinical trial | Closed |
| Transthyretin Amyloidosis Outcomes Survey (THAOS Registry) | Phase 2 study to evaluate ALN-TTRSC (Revusiran) in patients with Transthyretin (TTR) Cardiac Amyloidosis. | Registry | Closed at University of Calgary |
| NNC60119-0001 Research Study | A phase 2a research study to look at how a new medicine called NNC60119-0001 works and how safe it is for people who have heart disease due to Transthyretin (TTR) Amyloidosis. | Clinical trial | Active |
| The Vital Amyloidosis Study | A global phase 3, efficacy and safety study of NEOD001 in patients with AL Amyloidosis. | Clinical trial | Closed |
| The PRONTO Study | A global phase 2b study of NEOD001 in previously treated subjects with Light Chain (AL) Amyloidosis. | Clinical trial | Closed |
| ATTRIBUTE-CM Trial | A phase 3, randomized, double-blind, placebo-controlled study of the efficacy and safety of AG10 in subjects with Symptomatic Transthyretin Amyloid Cardiomyopathy | Clinical trial | Closed |
| CARDIO-TTRansform | A study to evaluate the efficacy and safety of Eplontersen (formerly known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in participants with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) | Clinical trial | Active |
| AQUARIUS | A phase 2, multicohort study of Daratumumab-based therapies in participants with Light Chain Amyloidosis (AL) | Clinical trial | Recruiting |
| AFFIRM-AL | A study to evaluate the efficacy and safety of Birtamimab in Mayo stage IV patients with AL Amyloidosis | Clinical trial | Recruiting |
| CAEL-101 | A study to evaluate the efficacy and safety of CAEL-101 in patients with Mayo stage 3b AL Amyloidosis. Phase 3a and 3b studies are both underway. | Clinical trial | Recruiting |
| Quality Amyloidosis Care in Alberta Project | A province-wide Transthyretin Amyloidosis Cardiomyopathy care pathway to enhance quality care assessment and delivery in Alberta | Quality improvement | Active |
Get involved
If you are interested in learning more about current or future opportunities to get involved in our research programs, get in touch.